Grant Stacy Goto
Known title: General Counsel & SecCIK: 0002040725
Associated companies
Transaction History
| ALB | ▲ Buy | Grant | 2,533 | $0 | 2/27/2025 | View on chart |
| ALB | ▲ Buy | Grant | 5,066 | $0 | 2/27/2025 | View on chart |
| ALB | ▲ Buy | Grant | 2,533 | $0 | 2/27/2025 | View on chart |
| ALB | ▲ Buy | Grant | 5,066 | $0 | 2/27/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
Albemarle Faces Q3 Earnings Test Amid Mixed Analyst Views
Albemarle is set to report third-quarter earnings on November 4, 2026, a key date for the battery materials sector. While some analysts note improving fundamentals, Mizuho recently lowered its price target to $130 and maintained a Neutral rating. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite recent positive news about supply chain resilience.
Albemarle Faces Q3 Earnings Test Amid Mixed Analyst Views. Albemarle is set to report third-quarter earnings on November 4, 2026, a key date for the battery materials sector. While some analysts note improving fundamentals, Mizuho recently lowered its price target to $130 and maintained a Neutral rating. The stock is currently trading near its 52-week low, reflecting ongoing market caution despite recent positive news about supply chain resilience.